Synonym
Cefonicid; Cefonicido; Cefonicidum; Monocef; BRN1066181; BRN-1066181; BRN 1066181
IUPAC/Chemical Name
(6R,7R)-7-((R)-2-hydroxy-2-phenylacetamido)-8-oxo-3-(((1-(sulfomethyl)-1H-tetrazol-5-yl)thio)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChi Key
DYAIAHUQIPBDIP-AXAPSJFSSA-N
InChi Code
InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
SMILES Code
O=C(C(N12)=C(CSC3=NN=NN3CS(=O)(O)=O)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
542.56
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Badillo E, Escudero E, Hernandis V, Galecio JS, Marín P. Pharmacokinetics of cefonicid in lactating goats after intravenous, intramuscular and subcutaneous administration, and after a long-acting formulation for subcutaneous administration. J Vet Pharmacol Ther. 2020 Jan;43(1):50-56. doi: 10.1111/jvp.12825. Epub 2019 Nov 14. PMID: 31724779.
2: Saltiel E, Brogden RN. Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1986 Sep;32(3):222-59. doi: 10.2165/00003495-198632030-00002. PMID: 3530703.
3: Dudley MN, Quintiliani R, Nightingale CH. Review of cefonicid, a long-acting cephalosporin. Clin Pharm. 1984 Jan-Feb;3(1):23-32. PMID: 6365414.
4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Cephalosporins. 2017 Jan 9. PMID: 31643977.
5: Wallace RJ Jr, Niefield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1982 Feb;21(2):231-5. doi: 10.1128/aac.21.2.231. PMID: 7041813; PMCID: PMC181864.
6: Pontzer RE, Kaye D. Cefonicid: a long-acting, second-generation cephalosporin. Antimicrobial activity, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984 Nov-Dec;4(6):325-33. doi: 10.1002/j.1875-9114.1984.tb03392.x. PMID: 6393074.
7: Swanson D, Maxwell RA, Johnson JT, Wagner RL, Yu VL. Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications. Antimicrob Agents Chemother. 1991 Jul;35(7):1360-4. doi: 10.1128/aac.35.7.1360. PMID: 1929293; PMCID: PMC245172.
8: Karki SD, Bentley DW, Luzier A, Taylor C, Morse GD. Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc. 1993 Aug;41(8):808-10. doi: 10.1111/j.1532-5415.1993.tb06174.x. PMID: 8340557.
9: Higbee M, Ramsey R, Swenson E. Cefonicid-induced seizure. Clin Pharm. 1987 Apr;6(4):271-2. PMID: 3665381.
10: Cazzola M, Polverino M, Guidetti E, Santangelo G, Paizis G, Monaco G, D'Amato G, Girbino G. Penetration of cefonicid into human lung tissue and lymph nodes. Chemotherapy. 1990;36(5):325-31. doi: 10.1159/000238784. PMID: 2209166.
